Net loss of Panacea Biotec reported to Rs 13.92 crore in the quarter ended September 2025 as against net profit of Rs 4.80 crore during the previous quarter ended September 2024. Sales declined 4.22% to Rs 141.13 crore in the quarter ended September 2025 as against Rs 147.35 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales141.13147.35 -4 OPM %-12.614.75 - PBDT-13.5310.67 PL PBT-21.871.99 PL NP-13.924.80 PL Powered by Capital Market - Live News

Panacea Biotec will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live News

Panacea Biotec announced that the Central Medical Services Society, Ministry of Health and Family Welfare, Government of India (�CMSS�) has, vide its Letter of Acceptance (LOA) dated 08 October 2025, accepted the Company`s offer for supply of bivalent oral polio vaccine (bOPV) against the tender issued by it in this regard. As per the LOA, the Company will supply the vaccine worth Rs.127.20 crore in several tranches over a period of 90 - 480 days from the date of issuance of LOA. Powered by Capital Market - Live News

Panacea Biotec has received a Letter of Award from UNICEF for a Long-Term Agreement for supply of bivalent oral polio vaccine (bOPV) to UNICEF starting from 1st April 2026 to 31st March 2030. The total award to the Company is for supply of bOPV in 10 and 20 vial presentation worth ~US$ 35.65 million (~Rs.315 crore) for a period of Q2 CY2026 and CY2027. Powered by Capital Market - Live News

Panacea Biotec announced that the Annual General Meeting(AGM) of the company will be held on 30 September 2025.Powered by Capital Market - Live News